The company will respond to the US FDA within the stipulated timelines
The United States Food and Drug Administration (US FDA) inspected Unit-V, an API manufacturing facility, of Apitoria Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma, situated at Industrial Development Area, Chemical Zone, Sangareddy, Telangana from December 01 to December 12, 2025.
At the end of the current inspection, a 'Form 483' was issued with 03 observations which are procedural in nature, and the company will respond to the US FDA within the stipulated timelines.
Suven Life Sciences achieved 100% patient enrolment in Phase-2b clinical trial of Ropanicant for MDO
Subscribe To Our Newsletter & Stay Updated